The board of directors at AbbVie Inc. has announced a quarterly cash dividend of $1.64 per share. This dividend is scheduled for payment on May 15, 2025, to shareholders who are recorded by the close of business on April 15, 2025.
AbbVie, which was established in 2013, has seen a substantial increase in its dividend by 310 percent since its inception. The company is also part of the S&P Dividend Aristocrats Index, highlighting its commitment to increasing dividends annually for over 25 years.
AbbVie's mission focuses on discovering and delivering innovative medicines and solutions aimed at addressing serious health issues and future medical challenges. The company operates across several therapeutic areas including immunology, oncology, neuroscience, and eye care, along with products and services under its Allergan Aesthetics portfolio.
For further information about AbbVie and its initiatives, interested parties can visit their website or follow them on various social media platforms such as LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Media inquiries can be directed to Gabby Tarbert at (224) 244-0111 or via email at gabrielle.tarbert@abbvie.com. Investors may contact Liz Shea at (847) 935-2211 or liz.shea@abbvie.com.